Vaishali Pharma vs Peers
- Market cap
- ₹106 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹5.86 – ₹10.99
Vaishali Pharma ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Vaishali Pharma. Its P/E of 22.5 compares with a peer median of 22.5.
Vaishali Pharma vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Vaishali Pharma | 8.14 | +0.49% | 106 | 22.5 | 2.85 | 14.5% | +18.5% |
| Vaishali Pharma | 8.14 | +0.49% | 106 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Vaishali Pharma peer comparison — frequently asked questions
Who are Vaishali Pharma's competitors?
Vaishali Pharma's listed peers in Drug Manufacturers - Specialty & Generic include Vaishali Pharma, ranked here by market capitalisation.
How does Vaishali Pharma's P/E compare with its peers?
Vaishali Pharma trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Vaishali Pharma's peers?
By market capitalisation, the largest company in the group is Vaishali Pharma at ₹106 crore, against ₹106 crore for Vaishali Pharma.
Same Data For Peers
Trade Vaishali Pharma With ATS
Track VAISHALI live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.